Detalles de la búsqueda
1.
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.
BMC Cancer
; 24(1): 735, 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38879498
2.
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients.
Int J Mol Sci
; 25(5)2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38473737
3.
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.
BMC Cancer
; 22(1): 623, 2022 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35672679
4.
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review.
Int J Mol Sci
; 23(13)2022 Jun 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35806079
5.
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Int J Med Sci
; 18(10): 2245-2250, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33859534
6.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol
; 235(11): 7900-7910, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31943171
7.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer
; 146(7): 1917-1929, 2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31330065
8.
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials.
BMC Cancer
; 20(1): 418, 2020 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32404154
9.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol
; 234(6): 7708-7717, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30536609
10.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 474-485, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29482983
11.
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
J Cell Physiol
; 233(3): 2313-2323, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28710865
12.
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
J Cell Physiol
; 232(6): 1571-1578, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27861874
13.
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Breast Cancer Res Treat
; 163(3): 587-594, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28353061
14.
ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study.
Future Oncol
; 13(17): 1517-1525, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28429617
15.
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
Future Oncol
; 13(30): 2791-2797, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29182361
16.
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.
J Cell Physiol
; 231(5): 986-91, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26449308
17.
Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
Future Oncol
; 11(3): 431-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25675124
18.
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
Breast Cancer Res Treat
; 147(3): 599-607, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25234842
19.
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Lancet Oncol
; 14(10): 981-8, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23883922
20.
Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.
Invest New Drugs
; 31(4): 1035-43, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23417697